Biocryst Pharmaceuticals (NASDAQ:BCRX) and Dyax Corp. (NASDAQ:DYAX) both rose yesterday on good news from Biocryst's phase 2A trial for BCX4161, a drug designed to treat hereditary angioedema (also known as HAE). Patients treated with BCX4161 had a statistically significant 35% decline in HAE attacks, and although the trial was small, the data appear encouraging. Dyax is also developing an HAE drug, DX-2930, and a Jefferies analyst noted that the positive news for Biocryst provides some reason for optimism for Dyax's drug (which is in early stage clinical trials) as well.
But which stock is the better buy? In the video below, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson give their take on which stock they'd prefer to own.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
The Most-Anticipated IPOs of 2018
Some of the most sought-after unicorns may make their public debut.
If You Like Dividends, You Should Love These 3 Stocks
Natural gas pipelines, hospitals, and wind towers power these lucrative dividends.
3 Top Healthcare Stocks to Buy Right Now
The S&P 500's top-performing stock last year and two under-the-radar small caps could be worth a closer look.